Takeda Pharmaceutical Co. Ltd. · TSE:4502

Takeda Pharmaceutical — Shareholder Meeting (July 2019)

5 slides from Takeda Pharmaceutical's shareholder meeting presentation, Jul 16, 2019

  1. Slide 1: Schematic Diagram of Takeda's Corporate Governance System, Including the Internal Control System

    Reference: Schematic Diagram of Takeda's Corporate Governance System, Including the Internal Control System General Meeting of Shareholders ‘Appointment/Dismissal of ‘Appointment/ Appointment/ Reroting members Reporting’ | | Dismissal of Reporting] Dismissal” Statement of opinion | | Werner Non-reap

  2. Slide 2: Directors' Compensation Policy

    Directors' Compensation Policy 1. Guiding Punciples The Company's compensation system for Directors has the following guiding principles under the corporate governance code to achieve management objectives: To attract, retain and motivate managerial talent to realize "Vision 2025" + To increase corp

  3. Slide 3: Compensation Mix for External Directors and Audit & Supervisory Committee Members

    required to hold 75% of their vested share portion until they leave the Company. Bonus is not available for this category of Director. Committee retainers are paid with Basic Compensation for the chair of board meeting, chair of the compensation committee, and chair of Nomination Committee. The curr

  4. Slide 4: Performance-based Compensation: Special Performance Share Awards and Annual Bonus

    corporate initiatives and which are aligned with shareholder expectations. Performance against established KPIs for special Performance Share awards are determined independently each year over a three-year period, with shares becoming vested after performance has been determined for the applicable p

  5. Slide 5: 5. Governance

    5. Governance The Compensation Committee has been established with an External Director as its Chairperson and with the majority of members being External Directors, to serve as an advisory organization for the Board of Directors to ensure the appropriateness of Directors' compensation, etc. and the

Takeda Pharmaceutical — Shareholder Meeting (July 2019) on 6ix